Diagnosis and management of EF in the setting of cancer immunotherapy requires close collaboration between patient’s oncologist, dermatologist, and rheumatologist.
With responses to ICIs taking 2 to 3 months, administration of these therapies to patients with poor life expectancies may not be appropriate.
Patients with advanced non-small cell lung cancer who did not have disease progression after chemoradiotherapy appeared to have a long-term survival benefit with durvalumab.
Patients with NSCLC who did not respond to immune checkpoint blockade had unique molecular characteristics, revealing possible therapeutic targets.
A retrospective cohort analysis found that patients with DLBCL who experienced infusion reactions during treatment with rituximab had prolonged overall survival. In addition, progression-free survival was affected in subsets of patients with DLBCL.
Raising the dose of bevacizumab does not appear to add clinical benefit for adult and pediatric patients with neurofibromatosis type 2 and hearing loss.
A phase 3 trial looking at nivolumab and ipilimumab in advanced melanoma has reported increased survival with the combination, but notable toxicities.
No significant differences in PROs were observed among patients treated with subsequent durvalumab after chemoradiation therapy for stage III unresectable NSCLC compared with those who received subsequent placebo.
Among patients who were naive to ALK inhibition, the overall response rate was 83% for the 450-mg dose and 60% for the 300-mg dose.
Could myeloma-associated antibodies could one day serve as biomarkers for predicting which patients will benefit from isatuximab?
